Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.

PubWeight™: 1.37‹?› | Rank: Top 10%

🔗 View Article (PMC 4071896)

Published in Can J Gastroenterol Hepatol on January 01, 2014

Authors

Giada Sebastiani, Peter Ghali, Phil Wong, Marina B Klein, Marc Deschenes, Robert P Myers

Articles citing this

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19

FibroScan® access in Canada: Time for reform, a call for universal access. Can J Gastroenterol Hepatol (2015) 0.98

Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. Can J Gastroenterol Hepatol (2015) 0.97

Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92

Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85

Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One (2015) 0.81

Out with the old and in with the new: hepatic fibrosis assessment in Canada. Can J Gastroenterol Hepatol (2014) 0.80

Human immunodeficiency virus and liver disease: An update. Hepatology (2015) 0.80

Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis (2015) 0.77

Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis. Ont Health Technol Assess Ser (2015) 0.76

Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2015) 0.76

A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C. Clin Transl Med (2016) 0.75

Improving access to transient elastography in Canada will need more than evidence-based guidelines and technical health assessment. Can J Gastroenterol Hepatol (2015) 0.75

Articles cited by this

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55

Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (2012) 11.03

Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19

Liver biopsy. Hepatology (2009) 7.61

EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82

Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol (2010) 5.78

Diagnosis and management of autoimmune hepatitis. Hepatology (2010) 5.27

Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17

Alcoholic liver disease. Hepatology (2010) 5.04

EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45

Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00

A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68

EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol (2012) 2.52

Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology (2012) 2.47

The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol (1999) 2.18

The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15

The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci (1979) 2.12

Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int (2008) 2.09

Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology (2012) 1.93

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med (2000) 1.55

NS5A inhibitors in the treatment of hepatitis C. J Hepatol (2013) 1.36

Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol (2008) 1.29

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS (2003) 1.27

Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol (2012) 1.27

Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J Hepatol (2006) 1.25

Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol (2011) 1.18

Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology (2013) 1.07

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int (2008) 1.04

A survey of current liver biopsy practice patterns. J Clin Gastroenterol (2002) 1.03

[Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region]. Gastroenterol Clin Biol (2003) 0.97

How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat (2012) 0.92

A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J Hepatol (2012) 0.92

Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87

Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can J Gastroenterol (2012) 0.86

Diagnostic usefulness of percutaneous liver biopsy in HIV-infected patients with fever of unknown origin. J Infect (1999) 0.80

Evolution of the determinants of chronic liver disease in Quebec. Chronic Dis Inj Can (2013) 0.77

Articles by these authors

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med (2009) 3.70

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology (2007) 3.29

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15

Weekend versus weekday admission and mortality from gastrointestinal hemorrhage caused by peptic ulcer disease. Clin Gastroenterol Hepatol (2008) 2.89

A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol (2013) 2.73

Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50

A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol (2009) 2.47

FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol (2007) 2.34

Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26

Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24

Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23

Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2013) 2.20

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19

U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18

Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06

Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05

Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. J Clin Gastroenterol (2014) 1.98

Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India. PLoS Med (2008) 1.96

Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86

A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol (2009) 1.84

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78

Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76

Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc (2012) 1.73

Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2012) 1.71

Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet (2010) 1.69

Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int (2008) 1.64

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (2011) 1.63

Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nat Genet (2010) 1.62

Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS (2011) 1.61

HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol (2010) 1.60

Epidemiology of gallstones. Gastroenterol Clin North Am (2010) 1.60

Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59

Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One (2012) 1.56

Predicting in-hospital mortality in patients undergoing complex gastrointestinal surgery: determining the optimal risk adjustment method. Arch Surg (2011) 1.54

A case of valproate-induced hyperammonemic encephalopathy: look beyond the liver. CMAJ (2007) 1.53

Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation (2012) 1.52

Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol (2011) 1.40

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol (2005) 1.38

Early continence outcomes of posterior musculofascial plate reconstruction during robotic and laparoscopic prostatectomy. BJU Int (2008) 1.36

Virologic and immunologic response to HAART, by age and regimen class. AIDS (2010) 1.34

Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol (2006) 1.34

Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol (2006) 1.32

Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS (2009) 1.32

The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol (2004) 1.32

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Hum Mol Genet (2012) 1.32

Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr (2007) 1.28

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS (2003) 1.27

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS (2004) 1.27

Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev (2008) 1.27

Cohort profile: the Canadian Observational Cohort collaboration. Int J Epidemiol (2010) 1.27

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol (2002) 1.25

Peering at peer review revealed high degree of chance associated with funding of grant applications. J Clin Epidemiol (2006) 1.21

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS (2010) 1.19

Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol (2002) 1.18

Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol (2009) 1.18

CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther (2010) 1.13

Meta-analysis of transarterial embolization in patients with unresectable hepatocellular carcinoma. Radiology (2003) 1.13

Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One (2009) 1.12

Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis (2011) 1.11

Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One (2013) 1.08

Prediction of liver fibrosis progression by non-invasive tests in chronic hepatitis C: the impact of validation. J Hepatol (2012) 1.08

A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr (2010) 1.05

Re: Francesco Montorsi, Timothy G. Wilson, Raymond C. Rosen, et al. best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena consensus panel. Eur Urol 2012;62;368-81. Eur Urol (2012) 1.05

The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol (2004) 1.04

Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol (2002) 1.02

Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol (2005) 1.02

Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges. Womens Health (Lond Engl) (2009) 1.00

Morbidity and mortality following colorectal surgery in patients with end-stage renal failure: a population-based study. Dis Colon Rectum (2010) 1.00

A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol (2013) 1.00

Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis (2013) 1.00

Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg (2011) 0.99

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98

Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology (2011) 0.97

Noninvasive diagnosis of liver fibrosis: The importance of being reimbursed. Can J Gastroenterol Hepatol (2015) 0.97

Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis (2013) 0.97

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 0.97

Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol (2013) 0.97

Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97

Postoperative complications following colectomy for ulcerative colitis: a validation study. BMC Gastroenterol (2012) 0.96

Validity of administrative data for the diagnosis of primary sclerosing cholangitis: a population-based study. Liver Int (2011) 0.96

Prevention of HIV-associated opportunistic infections and diseases in the age of highly active antiretroviral therapy. Expert Rev Anti Infect Ther (2004) 0.96

Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One (2013) 0.95

The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95

Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol (2002) 0.95

Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing. J Mol Med (Berl) (2012) 0.94